ClinicalTrials.gg
CompletedNCT05765487Updated Sep 4, 2025

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%

A Phase 1 interventional study of Sildenafil and Vehicle in Sexual Arousal Disorder, sponsored by Daré Bioscience, Inc.. Completed at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Daré Bioscience, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Sexual Dysfunctions, Psychological with a site in Canada — 1 open to participants now, 1 under way, none of them phase 3. Sexual Dysfunctions, Psychological · Canada.

Enrollment
26th of 26
13 · median 586
Started
2023
the only one that year
Phase 1
Only one
of the 28
Registered
27th of 28
by date
Lead sponsor
1 of 28
Daré Bioscience, Inc.

Among the 28 studies in Sexual Dysfunctions, Psychological with a site in Canada, this one is the 26th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 1, and was the 27th registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

1 of the 28 studies in Sexual Dysfunctions, Psychological with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Sexual Dysfunctions, Psychological with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare thermography images in normal healthy premenopausal women after the application of Sildenafil Cream, 3.6%, L-arginine cream, and placebo cream. Participants will be shown a series of explicit videos to elicit a change in genital temperature before and after application of cream.

03

Conditions studied

  • Sexual Arousal Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be a premenopausal woman at least 18 years of age.
  • Subject must be willing to avoid high protein meals and follow dietary guidance provided by the study site staff for the duration of the study.
  • Women of must be using an acceptable form of (i.e., intrauterine system [IUS], progestin and/or estrogen-containing hormonal contraceptives, contraceptive patch, contraceptive implant, contraceptive ring, or contraceptive injection) or the copper-containing intrauterine device (IUD) and must be on a stable dose or have had the insert/implant for at least 1 month without complication prior to Visit 1 and agree to continue to stay on their birth control for the duration of the study. Condoms (latex or polyisoprene only) are not considered an acceptable form of birth control but may be used to prevent exposure to sexually transmitted infections. An attempt will be made to enroll at least 30% of women who are using hormonal contraception and at least 30% who are not.
  • Subject reports she has viewed heterosexual pornography prior to Visit 1 and is sexually aroused from watching heterosexual porn or sexually explicit videos depicting men and women engaging in sexual activity.
  • Subject has a (BMI) \< 38 kg/m². Subjects with a BMI >30 kg/m2will be visually evaluated to ensure that there will not be physical interference with viewing the areas of interest by the thermography camera. If the investigator deems that interference is likely due to BMI, the subject will be excluded.
  • Subject has a normal at Visit 1.
  • Subject is capable of understanding and complying with the protocol and agrees to sign the document.
  • Subject has been sexually active (in the past 4 weeks since Visit 1). Sexual activity can include caressing, foreplay, masturbation, and vaginal intercourse.
  • Subject is fluent in the English language.
  • Subject is willing to trim pubic hair (if necessary) to allow for accurate genital temperature readings and visualization of the genital regions of interest.
  • Subject has had a Pap smear performed within three years prior to Visit 1 and can provide documentation indicating results that are either normal or atypical squamous cells of undetermined significance (ASCUS) but negative for Human Papilloma Virus (HPV) (based on current guidelines as published by the U.S. Prevention Services Task Force). If the subject cannot provide documentation, a Pap smear will be performed at Visit 1. Subjects with abnormal findings will be excluded from study participation and be referred for follow-up medical care as appropriate.
  • Subject is in good health for age, as determined by physical and gynecological history and examination at Visit 1.
  • Subject agrees to withhold from smoking tobacco products 24 hours prior to all visits.
  • Subject agrees to use compatible condoms (latex or polyisoprene) if she chooses to engage in vaginal or anal intercourse with her partner and abstain from receptive oral sex throughout the Double-Blind Dosing Phase and for seven days following the completion of Visit 4 to avoid potential partner exposure to the IP and to help prevent the transmission of sexually transmitted infections. Condoms should be used concurrently with subject's acceptable contraceptive method.
  • Subjects must agree to not use vaginal or vulvar lubricants, spermicides, creams or gels, contraceptive foams, or vaginal douche products from Visit 1 until after the follow-up safety call is completed 7±3 days after Visit 4.

Exclusion criteria

Exclusion Criteria:

  • Subject is nursing or pregnant (based on positive urine pregnancy test) or wishes to become pregnant during the study period.
  • Subject has any disorder or a history of any disorder that may prevent the successful completion of the study in the opinion of the Investigator.
  • Subject has used any topical hormone replacement therapy (HRT) applied locally to the genitals in within three months of Visit 1.
  • Subject has a significant cardiovascular, hepatic, metabolic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, genitourinary, or psychiatric disease or other unstable medical condition that would contraindicate administration of study medication, interfere with study evaluation, limit study participation, or confound the interpretation of study results in the opinion of the Investigator.
  • Subjects with controlled, treated thyroid disease on a stable medication for the past 6 months will be considered eligible. Thyroid Stimulating Hormone (TSH) must be within normal range (confirmed by laboratory test).
  • Subjects with controlled, treated hypertension on a stable dose of ACE Inhibitors or Angiotensin II Receptor Blockers for the past 6 months will be considered eligible.
  • Subject had an active ulcer or bleeding disorder.
  • Subject is actively menstruating at Visit 1 or has reported abnormal spotting in the 3 months preceding Visit 1.
  • Subject has a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to Visit 1; or any history of coronary disease-causing angina; or congestive heart failure requiring medical intervention.
  • Subject has retinitis pigmentosa or sickle cell anemia or related anemias, even if the subject feels clinically well at the time of Visit 1. Subjects with retinitis pigmentosa will be identified by specifically asking whether they have the condition, if there are visual signs and symptoms of the condition (including questioning subjects as to whether they have difficulty seeing at night or in low light, and if they have any visual field deficits that indicate a loss of peripheral or central vision), or if there is a family history.
  • Subject has a history of orthostatic hypotension or orthostatic hypotension which is present at Visit 1, defined as a drop in systolic blood pressure ≥ 20 mm Hg, a drop in diastolic blood pressure ≥ 10 mm Hg or experiencing lightheadedness or dizziness at 1 or 3 minutes after the change in position from supine to standing.
  • Subject reports a history of sexual dysfunction (e.g., anorgasmia, vaginismus, hypoactive sexual desire disorder, arousal difficulties etc.).
  • Patient has dyspareunia, vulvovaginal infection or inflammation, inflammatory disorders of the vulva or vagina, vestibulodynia, clitorodynia, Genitourinary Syndrome of Menopause (GSM) or vulvovaginal atrophy.
  • Subject has insulin dependent type 1 or type 2 diabetes.
  • Subjects who do not demonstrate a greater positive slope for genital temperature change over time during the Sexually Explicit Video Session as compared to the Neutral Video Session during the 'no-cream' familiarization session at Visit 1 will not be eligible to advance into the Double-Blind Dosing Phase of the study. Any positive slope (i.e., any genital temperature increase, slope>0) during the sexually explicit file viewed in Visit 1 is considered qualifying for subjects to proceed into the double-blind dosing phase.
  • Patient has undergone major pelvic surgery or abdominal surgery that may have caused nerve damage, including, vulvectomy and vestibulectomy.; neurological impairment due to diabetes, stroke, pelvic nerve damage secondary to trauma, cancer treatments, myasthenia gravis, multiple sclerosis or spinal cord damage.
  • With the exception of anxiety and depression, patient has any current and/or previously reported diagnoses of axis I disorders (e.g., schizophrenia, bipolar disorder) including delirium, dementia and amnestic disorders.
  • Patients diagnosed with anxiety or depression must be controlled, as determined by the Investigator, and if on a medication (i.e., SSRIs, SNRIs, buspirone, bupropion and benzodiazepines), on a stable dose for at least the past 6 months.
  • Patients who have any history of antipsychotic therapy within the last year will be excluded unless given for diagnosis of anxiety and/or depression and on a stable dose for the past 6 months if taking currently.
  • Subject has a history of cancer, other than basal cell carcinoma.
  • Subject has any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article in the opinion of the Investigator.
  • Subject has a history of drug abuse within 1 year prior to Visit 1.
  • Subject has a history of alcoholism within 1 year prior to Visit 1, admitted alcohol abuse, average consumption of more than 1 standard unit of alcohol per day (a standard unit equals 12 ounces of beer, 1½ ounces of 80-proof alcohol, or 6 ounces of wine).
  • Subject has a history of non-arteritic ischemic optic neuropathy (NAION).
  • Subject has had treatment currently or within 1 month (28 days) prior to Visit 1 with any of the following:

    1. Dehydroepiandrosterone (DHEA), excluding intravaginal DHEA, testosterone and other androgens, tamoxifen, raloxifene, and other selective estrogen receptor modulators (SERMs)
    2. Any antihypertensive (excluding ACE Inhibitors or Angiotensin II Receptor Blockers), clonidine, alpha blockers or nitrate containing medications.
    3. Beta blockers or other drugs that affect the autonomic nervous system and/or cardiovascular system
    4. Any approved or experimental medications or treatments used to enhance the sexual response (e.g., oral sildenafil, L-arginine)
    5. Any drugs or supplements that may alter amino acid or vitamin status, such as drugs or supplements containing L-arginine or Citrulline.
  • Subjects who are currently being treated daily with weak, moderate, and strong inhibitors and inducers of and CYP2C9 enzymes (e.g., CYP3A4: ketoconazole, clarithromycin, verapamil, diltiazem, St. John's Wort / CYP2C9: fluconazole, oxandrolone, fluvastatin, and metronidazole), Seville oranges, or any prescription, over-the-counter (OTC) medications, or herbal products known to inhibit or induce the 2 enzymes listed above must agree to continue taking the supplement or medication at approximately the same time each day for the duration of the study period, assuming the Investigator or subject's provider deems appropriate. If the subject is using the supplement or medication PRN, that subject must wash out (i.e., 6 half-lives) for the duration of the study period (Visit 1 to Visit 3), assuming the Investigator or subject's provider deems appropriate. If the subject takes any prescription or OTC drugs at the direction of a health care provider that are inhibitors or inducers of CYP3A4 and CYP2C9, that provider should be consulted before medications are stopped for the purposes of study participation.
  • Subject has positive findings from the urine drug screen (e.g., amphetamines, barbiturates, benzodiazepines, cocaine, methadone, and opiates).
  • Subject has positive findings for sexually transmitted infection (gonorrhea, chlamydia, trichomoniasis), or (HIV) antibodies.
  • Subject reports having an outbreak (blisters, warts or vesicles) due to any of the following sexually transmitted diseases: genital herpes or HPV at any time point in the past three months.
  • Subject has participated in any clinical research study evaluating another drug or therapy within 30 days before Visit 1 (or 6 half-lives of the investigational agent, whichever is longer).
  • Subject has any abnormal findings on vulvar-vaginal examination performed during the physical and gynecological exams at Visit 1 (e.g., genital skin breaks, irritation, dermatoses, or lesions).
  • Subject has a genital piercing(s) or plans to get a genital piercing(s) during the study period which could interfere with thermal camera data collection or study objectives, as determined by the Investigator.
  • Subject has moderate to severe current vaginitis, a vaginal infection including bacterial vaginosis (BV) or a yeast infection. The diagnosis of yeast infections should be made by the Investigator based on the physical and gynecological exams; the objective is to exclude women that are symptomatic. If the woman is not complaining of symptoms but the Investigator observes discharge, then a vaginal wet mount test should also be performed to confirm a diagnosis of yeast and Amsel criterion for confirmation of BV infection.
  • Subject has a pelvic or urinary tract infection.
  • Subject self-reports a known to any ingredients in the Investigational Product (IP).
  • Subject reports an orthopedic condition (e.g., labral tear, hip osteoarthritis) that may interfere with study participation, in the opinion of the Investigator, with regard to the thermography procedure during Visits 1 through 4.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    Sildenafil Cream, 3.6%

    Contains both Sildenafil and L-arginine

    Drug: Sildenafil

  • Placebo comparator
    Placebo Cream

    Contains L-arginine, no Sildenafil

    Drug: Placebo

  • Other
    Vehicle Cream

    Contains no L-arginine, no Sildenafil

    Drug: Vehicle

Interventions

  • Sildenafil Cream, 3.6%

  • DrugVehicle

    No Active or experimental ingredients

  • DrugPlacebo

    Cream with only L-arginine

06

What researchers measure

Primary outcomes

  1. Evaluate the difference in vulvar blood flow after the use of investigational products

    To evaluate and compare the impact of 2 grams of Sildenafil Cream 3.6%, Placebo Cream and Vehicle Cream on vulvar blood flow, as assessed by thermography in normal healthy premenopausal women.

    Time frame: 14 days

07

Study locations

1 site
  • Pharma Medica Research, Inc.
    Mississauga, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jan 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 13, 2023
StartActual
May 13, 2023
Primary completionActual
Jan 26, 2024
CompletionActual
Oct 21, 2024
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05765487
Lead sponsor
Daré Bioscience, Inc.
Collaborators
Strategic Science & Technologies, LLC
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
May 13, 2023
Primary completion
Jan 26, 2024
Completion
Oct 21, 2024
Last update
Sep 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion